Pioneering the development
of engineered IgM antibodies
for the treatment of cancer
Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies
November 22, 2019
November, 2019 – PEGS Europe, Lisbon Bruce Keyt, PhD, Chief Scientific Officer IGM Biosciences, Inc.,…
A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions
November 21, 2019
November, 2019 – PEGS Europe, Lisbon Daniel Chen, MD, PhD, Chief Medical Officer IGM Biosciences,…
IGM Biosciences to Present at Three Upcoming Investor Conferences
November 12, 2019
MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…
IGM Biosciences Announces Third Quarter 2019 Financial Results
November 7, 2019
MOUNTAIN VIEW, Calif., — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…
IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma
October 2, 2019
MOUNTAIN VIEW, Calif., Oct. 02, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company focused on…